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INTRODUCTIONANDAIMS: Prospective clinical trial to test the hypothesis that
prophylactic weekly use of urokinase locks in tunneled cuffed hemodialysis catheters
with a history of multiple thrombotic dysfunctions reduces the incidence of recurring
thrombotic dysfunction by at least 50%.
METHODS: Design: Prospective, multi-center, randomized, double-blinded, placebo-
controlled trial. Patients were allocated using block randomization with permuted
blocks of 4, stratified for the participating centers. Setting: Eight Belgian hemodialysis
high care and low care units. Participants: Adult prevalent patients undergoing hemo-
dialysis at least 3 times a week via a tunneled cuffed catheter and having presented at
least 2 separate thrombotic dysfunctions during the 6 months preceding inclusion.
Intervention: TaurolockTMU 25,000 once a week and TaurolockTMHEP500 after the
two other dialysis sessions in the TauroU group versus TaurolockTMHEP500 3 times a
week in the Control group. The Control group received the standard lock as a placebo
indistinguishable from the Taurolock UTM 25,000 once a week. Follow-up 6months.
Main outcomemeasures Incidence rate of thrombotic catheter dysfunction requiring
urokinase as primary outcome. Catheter removal for thrombosis and overall treatment
failure (catheter removal, systemic fibrinolysis and refractory thrombosis with impossi-
bility of catheter removal or systemic thrombolysis) as secondary outcomes.
RESULTS: 68 patients were randomized (N¼36 in the TauroU group, N¼32 in the
Control group) and followed for a total of 9821 catheter days at risk. 15/36 (42%) cath-
eters in the TauroU group required at least one therapeutic lock vs 23/32 (72%) in the
Control group (P¼0.012). A total of 24 urokinase locks (4.8/1000 catheter-days) were
administered in the TauroU group vs 59 (12.3/1000 catheter-days) in the Control
group (Rate ratio 0.39; 95%CI 0.23 to 0.63; P<0.0001). 2 catheters were removed for
resistant thrombosis in the Control group vs 0 in the TauroU group without significant
difference in the overall incidence of treatment failure. No bleeding complications
occurred during the study.
CONCLUSIONS: Taurolock U 25,000 once a week is highly efficient in preventing
recurring thrombotic dysfunction of tunneled cuffed catheters.
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INTRODUCTIONANDAIMS: It has been proposed that placement of an Arterio
Venous Access, (AVA) reduce renal function decline, but convincing evidence is lack-
ing. This study aimed to investigate the influence of AVA placement on GFR decline as
compared to placement of a peritoneal dialysis catheter, (PDC) at a similar time point.
METHODS: All pre-dialytic patients18 years in the Stockholm County, Sweden who
underwent surgery for an AVA or PDC betweenMarch 1, 2006 and September 30, 2012
were included. Information on diabetes and cardiovascular disease on or before surgery
date was obtained from clinical records. Prescribedmedication was ascertained by the
National Registry for Dispensed drugs. Information on laboratory measures of interest
(eGFRCKD-EPI, hemoglobin, potassium, albumin, proteinuria, phosphate, and calcium)
was collected 100 days before and after surgery. Patients were followed until start of
dialysis, death or for 100 days, whichever came first. The primary outcome was the dif-
ference in eGFR decline after surgery in those with AVA compared with PDC (intention
to treat). eGFR decline was estimated through linear mixed models with random inter-
cept and slope before and after surgery. The association between type of surgery (AVA/
PDC) and eGFR decline was studied in a linear regressionmodel adjusting for age, sex,
eGFR at the time of surgery and decline before surgery, medication, and plasma albu-
min. Sensitivity analyses were performed (propensity score matching, different model
specifications, and restricted analyses).
RESULTS: There were 435 patients with AVA placement and 309 with PDC as their
first line of treatment. The AVA patients were slightly older (64.5 versus 62.6 years),
andmore oftenmen (63.5% versus 62.5%). Compared with PDC, patients with AVA
hadmore cardiovascular disease and diabetes, but lower use of ESA and ACE/ARB. The
eGFR at the time of surgery was higher in patients who received an AVA (8.1 versus 7.0
ml/min/1.73m2) and they had a less rapid decline before surgery (-5.6 compared with -
6.7 ml/min/1.73m2/year for PDC). Both patients with AVA and PDC had slower
decline in eGFR after than prior to surgery. There was no difference in the eGFR decline
after surgery in AVA patients compared with PDC patients (AVA progressed -1.14 (-
2.38; 0.10) ml/min/1.73m2/year faster after surgery compared with PDC). Propensity
score matched analysis showed nomajor difference compared with the primary analysis
(adjusted eGFR decline was -2.33 (-8.45; 1.46) ml/min/1.73m2/year faster in AVA
patients).
CONCLUSIONS: In summary, this study shows no influence of Arterio Venous access
compared to PD catheter placement on the decline of eGFR. The progression of renal
function was not associated with the placement of an AV access. Thus, the need for dial-
ysis remains the main determinant for timing of AV access placement.
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INTRODUCTIONANDAIMS:Vascular access outcomes in haemodialysis (HD) are
critically important for patients and health professionals but trial-based evidence to
improve access-related outcomes is limited by the inconsistent and selective reporting
of outcomes. We aimed to establish a core outcome measure for vascular access to be
reported consistently in all trials in HD based on the shared priorities of patients and
health professionals.
METHODS:We conducted a systematic review of randomised trials in HD to assess
the frequency and consistency of vascular access outcomes; an international survey (in
English, Chinese, Malay, and Spanish languages) with patients, caregivers and health
professionals (i.e. clinicians, nurses, allied health professionals, researchers, policy mak-
ers, and other relevant stakeholders with expertise in HD) to rate and rank selected out-
comes using a 9-point Likert scale and BestWorst Scale; and amulti-stakeholder
consensus workshop to establish the core outcome for vascular access, describe reasons
for the participant’s choices and discuss feasibility aspects andmeasurement properties
of the proposed outcome measures.
RESULTS:Across 168 randomised trials published in the last 5 years, over 1400 out-
comemeasures to assess 23 vascular access outcomes were identified. Vascular access
function was the most frequently reported outcome (81% of trials) followed by infec-
tion (38%). In total, 984 participants (246 [25%] patients and caregivers and 738
[75%] health professionals) from 60 countries completed the survey and vascular
access function was identified as the top critically important outcome. Themes from
the consensus workshop indicated that function was considered the core outcome for
vascular access based on its broad applicability to all access types, the multidisciplinary
involvement to achieve a functioning access, and the impacts of access function on
quality of life, survival and various access-related outcomes. “The need for an interven-
tion tomaintain the use of the vascular access for HD” was considered a pragmatic and
feasible definition to measure vascular access function that is meaningful to patients
and clinicians. Both, “time to first intervention” and “intervention rates” were deemed
the most informative and responsive metrics.
CONCLUSIONS: The feasibility and reliability of the proposed core outcome measure
will be assessed in pilot studies prior to global implementation. Consistent reporting of
the core outcome vascular access function, defined as “the need for an intervention to
maintain the use of the vascular access for HD” in all trials in HD, will improve the reli-
ability, comparability, usability, and potential impact of trial-based evidence to inform
decision-making in HD.
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